Anzeige
Mehr »
Samstag, 06.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BR2 | ISIN: US1711262048 | Ticker-Symbol:
NASDAQ
05.09.25 | 19:17
29,200 US-Dollar
-5,84 % -1,810
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PELTHOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PELTHOS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PELTHOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPelthos Therapeutics Inc. - 8-K, Current Report1
DiOppenheimer initiates Pelthos Therapeutics stock with Outperform rating3
20.08.Ligand Q1 2025: Umsatz steigt um 46 %, strategische Fusion zu Pelthos angekündigt1
20.08.Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced2
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln
18.08.Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update502Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI...
► Artikel lesen
18.08.Pelthos Therapeutics Inc. - 8-K, Current Report1
13.08.Pelthos Therapeutics Inc. - 10-Q, Quarterly Report1
25.07.Pelthos Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
10.07.Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI365WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first...
► Artikel lesen
10.07.Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease1
10.07.Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI245JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially...
► Artikel lesen
02.07.Pelthos Therapeutics Inc. - 8-K, Current Report1
02.07.Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July411WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics...
► Artikel lesen
02.07.Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt6
02.07.Ligand completes merger, Pelthos to launch molluscum treatment2
02.07.Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics187Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company...
► Artikel lesen
27.06.Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting2
27.06.Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement175FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment...
► Artikel lesen
14.05.EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models2
13.05.Channel Therapeutics Corp - 10-Q, Quarterly Report1
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1